CK7 and CK19 in Bile Duct Cancer
CK7 and CK19 help identify bile duct cells and may support future bile-based monitoring in bile duct cancer and biliary tract cancers.
Understanding Bile Duct Cancer Pathology, IHC and Genomic Reports
Learn how bile duct cancer pathology, IHC markers and genomic reports help explain bile duct cancer diagnosis, tumour origin and treatment options.
Steve Holmes: Stage 4 Cholangiocarcinoma Survivor Story
Steve Holmes survived stage 4 cholangiocarcinoma after surgery, recurrence and immunotherapy. A patient story revealing the biology and decisions behind survival.
NRG1 Fusion Cholangiocarcinoma
Most patients miss pathways like this, not because they don’t qualify, but because rare fusion signals are never fully investigated in time. NRG1 Fusion Cholangiocarcinoma is now linked to a newly FDA-approved targeted therapy called BIZENGRI for patients carrying this rare fusion pathway.
HER2 biliary cancer trial Australia | Early-phase study (NCT05523947)\
A targeted, early-stage HER2 trial opens an option for a small, defined group of biliary cancer patients and requires precise selection and grounded expectations.
Inside Cholangio: Where It Begins
Most patients are told what their cancer is. Very few are shown where it begins. This article places you inside the system where cholangiocarcinoma starts, so you can understand what is happening and respond before options are lost.
CK7 and CK19 in Bile Duct Cancer
CK7 and CK19 help identify bile duct cells and may support future bile-based monitoring in bile duct cancer and biliary tract cancers.
Understanding Bile Duct Cancer Pathology, IHC and Genomic Reports
Learn how bile duct cancer pathology, IHC markers and genomic reports help explain bile duct cancer diagnosis, tumour origin and treatment options.
Steve Holmes: Stage 4 Cholangiocarcinoma Survivor Story
Steve Holmes survived stage 4 cholangiocarcinoma after surgery, recurrence and immunotherapy. A patient story revealing the biology and decisions behind survival.
NRG1 Fusion Cholangiocarcinoma
Most patients miss pathways like this, not because they don’t qualify, but because rare fusion signals are never fully investigated in time. NRG1 Fusion Cholangiocarcinoma is now linked to a newly FDA-approved targeted therapy called BIZENGRI for patients carrying this rare fusion pathway.
HER2 biliary cancer trial Australia | Early-phase study (NCT05523947)\
A targeted, early-stage HER2 trial opens an option for a small, defined group of biliary cancer patients and requires precise selection and grounded expectations.
Inside Cholangio: Where It Begins
Most patients are told what their cancer is. Very few are shown where it begins. This article places you inside the system where cholangiocarcinoma starts, so you can understand what is happening and respond before options are lost.
